In the premiere episode of The Cure Circle, host Dr. Smita Karpate speaks with Prof. Roland Schelker, clinician–scientist at the Leibniz Institute for Immunotherapy, whose work sits at the cutting edge of T-cell engineering, CAR-T therapy, and solid tumor immunotherapy.

What began as a routine pharma dinner in 2011 where Prof. Schelker first heard about CTLA-4 checkpoint antibodies became the moment that redirected his scientific career. Today, he is pioneering approaches that go beyond receptor design and focus on something deeper: T-cell fitness and stem-like memory T cells (TSCM) capable of renewing themselves and sustaining anti-tumor activity.

Drawing directly from real clinical experiences and translational research, this episode explores how immune cells can be reprogrammed to last longer, fight harder, and potentially change survival outcomes for patients with advanced cancers.

In this episode, Prof. Schelker and Dr. Karpate discuss:

• Why the next frontier of immunotherapy is not just better CAR receptors but fitter, stem-like T cells

• How T-cell exhaustion limits current therapies and how TSCM engineering may overcome it

• Why certain tumors (like synovial sarcoma and myxoid liposarcoma) are ideal for next-generation TCR/T-cell trials

• How academic centers bring therapies from discovery to GMP to regulatory approval to first-in-human studies

• The real-world challenges clinicians face when treating cytokine release syndrome and other toxicities

• The critical role of collaboration between researchers, clinicians, GMP teams, and pharma

• Why global access matters and how countries like India can become hubs for scalable, cost-effective cell therapy

• The emotional side of breakthrough responses: what it feels like when a patient with metastatic cancer enters remission

This conversation is a rare blend of scientific depth, clinical honesty, and global perspective.

Episode 1 sets the tone for The Cure Circle, a platform where innovators discuss not just what is possible in cell and gene therapy, but what is necessary to bring healing to every patient, everywhere.

Subscribe, share, and join us as we explore the people, the purpose, and the science shaping the future of cancer care.